The results of the research appear in this article, Regular Expression of PD-L1 on Circulating Breast Cancer Cells, published online inMolecular Oncology, and demonstrate that PD-L1 positive CTCs were found in 11 out of 16 sufferers with circulating tumor cells. This particular software of the CELLSEARCHSystem is usually for study purposes only and is not cleared by the US Food and Drug Administration.This publication potentially adds a new important application to the research use of the CELLSEARCHSystem to characterize CTCs for PD-L1. In performing their study, the investigators selected the CELLSEARCHSystem as an automated specialized platform that has demonstrated consistent, reproducible results.Due to the complexity of making the immunotherapy – which must be individually produced for each patient – there will be a six – to 12-month ramp-up period before it is available to all eligible sufferers. Patients should talk with their doctors to determine if they’re candidates for the vaccine, noted Kantoff, who is the director of the Lank Middle for Genitourinary Oncology at Dana-Farber/Brigham and Women’s Cancer Center, chief of the Division of Solid Tumor Oncology and chief medical study officer at Dana-Farber, and professor of medicine at Harvard Medical College.




COMPANY PROFILE | CUSTOMER SERVICE | PRODUCTS
LEADING PRODUCTS | CATALOGUE | TO CONTACT US

info@uniformetecnic.com